TRAMETINIB
trametinib 2 mg tablet, 30
TRAMETINIB (11819C)
11819C
Manner of administration:Oral
Restriction
Indication: Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma
Treatment phase: Initial treatment
Restriction
Indication: Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 3 | DPMQ: $7,158.16 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Mekinist | |||||